Development
Boston Scientific Corporation
BSX
$102.83
$0.400.39%
NYSE
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 14.90% | 11.26% | 10.94% | 12.00% | 3.68% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 14.90% | 11.26% | 10.94% | 12.00% | 3.68% |
| Cost of Revenue | 13.09% | 12.32% | 4.70% | 8.69% | 4.17% |
| Gross Profit | 15.73% | 10.78% | 13.82% | 13.55% | 3.45% |
| SG&A Expenses | 18.57% | 9.72% | 16.22% | 14.62% | 0.87% |
| Depreciation & Amortization | 4.52% | 2.97% | 2.94% | 2.53% | 3.65% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.43% | 9.58% | 9.79% | 10.30% | 2.57% |
| Operating Income | 17.30% | 20.12% | 16.99% | 20.95% | 9.81% |
| Income Before Tax | 27.59% | 148.57% | 23.48% | 187.10% | 226.45% |
| Income Tax Expenses | -99.61% | 84.21% | 83.53% | 191.11% | 880.77% |
| Earnings from Continuing Operations | 259.29% | 168.09% | 3.85% | 185.45% | 47.37% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 260.00% | 168.09% | 3.85% | 185.45% | 47.37% |
| EBIT | 17.30% | 20.12% | 16.99% | 20.95% | 9.81% |
| EBITDA | 13.41% | 14.92% | 12.72% | 14.81% | 6.63% |
| EPS Basic | 292.04% | 183.21% | 4.88% | 210.86% | 56.68% |
| Normalized Basic EPS | 9.68% | 31.99% | 14.65% | 178.31% | 35.63% |
| EPS Diluted | 285.78% | 183.33% | 5.88% | 210.86% | 56.68% |
| Normalized Diluted EPS | 9.56% | 31.82% | 14.53% | 178.40% | 35.71% |
| Average Basic Shares Outstanding | 2.28% | 2.30% | 1.15% | 0.56% | 0.53% |
| Average Diluted Shares Outstanding | 2.39% | 2.43% | 1.28% | 0.53% | 0.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -1.00% | -1.00% | -0.04% | -0.65% | -0.32% |